Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

One example of such a dispute is over access to Vertex’s cystic fibrosis drug ... better antibiotics use, fast uptake of biosimilars and better mental health services. These are not necessarily ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Successful uptake of new technology is a matter of emotions -- and with 4 in 5 companies saying they're failing to capitalize on its potential, managers need to know how to deal with them ...

Vertex Pharmaceuticals recently obtained approval for its non-opioid pain medication. The drug could become a blockbuster and a key part of Vertex's portfolio. The stock has been rising in value ...

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

“Traditional suburbs have overtaken inner-city suburbs in EV uptake. Our data shows that outer metropolitan suburbs have accounted for 43 per cent of uptake. When combining outer metropolitan, ...

ELLIS COUNTY, Texas — Mammoths roamed across North Texas tens of thousands of years ago, and the head of one of them will soon be on display, as a mammoth skull was uncovered in Ellis County ...